Transplant outcomes in bone marrow failure syndromes and hemoglobinopathies.

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potential cure for most bone marrow (BM) failure syndromes and hemoglobinopathies. Over the past decade, umbilical cord blood (UCB) has been used more frequently as a stem cell source in patients who lack a suitable BM donor. Although graft failure remains a significant problem, UCB transplantation (UCBT) using the optimal conditioning regimen can be a salvage treatment for patients without a suitable BM donor and warrants evaluation in further prospective studies.

• Authors: Margaret L MacMillan, Mark C Walters, Eliane Gluckman
• Journal: Seminars in hematology (Semin Hematol) Vol. 47 Issue 1 Pg. 37-45 (Jan 2010) ISSN: 1532-8686 [Electronic] United States
• PMID: 20109610 (Publication Type: Journal Article, Review)
• Copyright: (c) 2010 Elsevier Inc. All rights reserved.

Topics

• Blood Banks
• Blood Donors (supply & distribution)
• Bone Marrow Diseases (surgery)
• Cord Blood Stem Cell Transplantation (adverse effects)
• Hematopoietic Stem Cell Transplantation (adverse effects)
• Hemoglobinopathies (surgery)
• Humans
• Patient Selection
• Transplantation, Homologous
• Treatment Outcome